Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05396781 · ClinicalTrials.gov registry record · Phase 2
Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening
A Phase 2 study, sponsored by Anandasabapathy, Sharmila, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05396781: Completed Phase 2 study, sponsored by Anandasabapathy, Sharmila, M.D..
NCT05396781 is a Phase 2 study that has completed, run by Anandasabapathy, Sharmila, M.D.. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05396781, a Phase 2 study, has completed, sponsored by Anandasabapathy, Sharmila, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broader use of this device by non-experts, the investigators recently developed a prototype marHRME platform with an automated, augmented reality (AR)-interpretation that provides an overlaid endoscopic + micro-endoscopic view, facilitating diagnosis and biopsy targeting.
Primary Outcome
The number of neoplastic biopsies/total number of biopsies obtained in patients who received biopsies.
Interventions
- DRUG Proflavine
- DEVICE Mobile, Augmented High Resolution Microendoscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 2 |
What the finished NCT05396781 record still lists
NCT05396781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Proflavine is the first listed.
NCT05396781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05396781 about?
NCT05396781 is a clinical study titled "Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening". The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broad...
What is the current status of trial NCT05396781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-01-13. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT05396781?
The interventions under investigation include: Proflavine (DRUG), Mobile, Augmented High Resolution Microendoscope (DEVICE).
Who is sponsoring clinical trial NCT05396781?
This trial is sponsored by Anandasabapathy, Sharmila, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05396781's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI